Manuel Monreal/X
Aug 31, 2025, 07:05
RIETE Registry Data: Manuel Monreal on VTE vs. Bleeding Risks in Cancer Patients
Manuel Monreal, coordinator of the RIETE registry, posted on X:
”The risk of the composite of fatal PE or recurrent VTE within 90 days is much higher than major bleeding in lung, breast, hematologic or pancreatic cancers
No major differences in GU or CI cancers
Should all cancer patients with acute VTE receive the same treatment strategy?”
Find it here.
Title: Variation in Venous Thromboembolism Outcomes Based on Primary Cancer Site: A RIETE Registry Analysis
Authors: Javier Trujillo-Santos, Cihan Ay, Behnood Bikdeli, David Jiménez, Aurora Villalobos, Luciano López-Jiménez, Montserrat Pérez-Pinar, Javier Pagán-Escribano, Maurizio Ciammaichella, Manuel Monreal
Stay updated with Hemostasis Today.
Aurora Villalobos
Behnood Bikdeli
Bleeding Risk
cancer
Cihan Ay
David Jimenez
Hematology
Hemostasis Today
Javier Pagán-Escribano
Javier Trujillo-Santos
Luciano López-Jiménez
Manuel Monreal
Maurizio Ciammaichella
Montserrat Pérez-Pinar
PE
Pulmonary embolism
RIETE registry
venous thromboembolism (VTE)
-
Dec 13, 2025, 17:38Amaliris Guerra: Science We Do Has Real Human Stakes
-
Dec 13, 2025, 17:31Natasha Jolakoski on Rethinking Lead-in Strategies in VTE
-
Dec 13, 2025, 17:20James Morrissey Shares the Explanation of A Literally 30 Years Worth of TF Biochemistry
-
Dec 13, 2025, 17:03Danny Hsu: Aspirin May Prevent Cancer Metastases?
-
Dec 13, 2025, 16:33Ana Cláudia de Souza: Opening Event for ÁRTEMIS-Brasil, a PROADI-SUS Project
-
Dec 13, 2025, 16:19Chandra Viswanathan on Altruism and Donating Blood
-
Dec 13, 2025, 16:09Brehanna Edwards Compares Apixaban or Rivaroxaban in VTE
-
Dec 13, 2025, 15:36Jeyaraj Pandian’s Visit to China to Support Advancement and Standardization of Stroke Care
-
Dec 13, 2025, 15:20An Important Step Forward in ITP: Shreeram Aradhye Shares Ianalumab Phase III Results!